Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Isoforms of the class II transactivator protein.

Barbieri G, Deffrennes V, Prod'homme T, Vedrenne J, Baton F, Cortes C, Fischer A, Bono MR, Lisowska-Grospierre B, Charron D, Alcaïde-Loridan C.

Int Immunol. 2002 Aug;14(8):839-48.

PMID:
12147620
2.

Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines.

Rodríguez T, Méndez R, Del Campo A, Aptsiauri N, Martín J, Orozco G, Pawelec G, Schadendorf D, Ruiz-Cabello F, Garrido F.

Immunogenetics. 2007 Feb;59(2):123-33. Epub 2006 Dec 20.

PMID:
17180681
3.

Class II transactivator (CIITA) isoform expression and activity in melanoma.

Baton F, Deruyffelaere C, Chapin M, Prod'homme T, Charron D, Al-Daccak R, Alcaide-Loridan C.

Melanoma Res. 2004 Dec;14(6):453-61.

PMID:
15577315
6.

MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?

Walter W, Lingnau K, Schmitt E, Loos M, Maeurer MJ.

Br J Cancer. 2000 Nov;83(9):1192-201.

7.

Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter.

Deffrennes V, Vedrenne J, Stolzenberg MC, Piskurich J, Barbieri G, Ting JP, Charron D, Alcaïde-Loridan C.

J Immunol. 2001 Jul 1;167(1):98-106.

8.
9.

Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA.

Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B.

Science. 1994 Jul 1;265(5168):106-9.

PMID:
8016643
10.

Structural and functional characteristics of a dominant-negative isoform of porcine MHC class II transactivator.

Quinn G, Bower R, Dos-Santos Cruz G, Giovino M, Xu Y, Patience C, Schuurman HJ.

Eur J Immunogenet. 2003 Aug;30(4):259-70.

PMID:
12919287
11.

Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines.

Goodwin BL, Xi H, Tejiram R, Eason DD, Ghosh N, Wright KL, Nagarajan U, Boss JM, Blanck G.

Cell Growth Differ. 2001 Jun;12(6):327-35.

12.

HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: acquisition of antigen processing and presentation capacity.

Sartoris S, Valle MT, Barbaro AL, Tosi G, Cestari T, D'Agostino A, Megiovanni AM, Manca F, Accolla RS.

J Immunol. 1998 Jul 15;161(2):814-20.

13.

Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas.

Kanaseki T, Ikeda H, Takamura Y, Toyota M, Hirohashi Y, Tokino T, Himi T, Sato N.

J Immunol. 2003 May 15;170(10):4980-5.

14.

Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells.

Radosevich M, Song Z, Gorga JC, Ksander B, Ono SJ.

Invest Ophthalmol Vis Sci. 2004 Sep;45(9):3185-95.

PMID:
15326139
15.

CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells.

Meissner M, Whiteside TL, Kaufmann R, Seliger B.

Arch Dermatol Res. 2009 Feb;301(2):189-93. doi: 10.1007/s00403-008-0922-6. Epub 2008 Dec 23.

PMID:
19104823
16.

Collagen and major histocompatibility class II expression in mesenchymal cells from CIITA hypomorphic mice.

Xu Y, McDonald J, Perloff E, Butticè G, Schreiber BM, Smith BD.

Mol Immunol. 2007 Mar;44(7):1709-21. Epub 2006 Sep 18.

PMID:
16982097
17.

TGF-beta suppresses IFN-gamma induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression.

Lee YJ, Han Y, Lu HT, Nguyen V, Qin H, Howe PH, Hocevar BA, Boss JM, Ransohoff RM, Benveniste EN.

J Immunol. 1997 Mar 1;158(5):2065-75.

PMID:
9036950
18.

Regulation of MHC class II expression in glioma cells by class II transactivator (CIITA).

Takamura Y, Ikeda H, Kanaseki T, Toyota M, Tokino T, Imai K, Houkin K, Sato N.

Glia. 2004 Mar;45(4):392-405.

PMID:
14966870
20.

CIITA-dependent and -independent class II MHC expression revealed by a dominant negative mutant.

Zhou H, Su HS, Zhang X, Douhan J 3rd, Glimcher LH.

J Immunol. 1997 May 15;158(10):4741-9.

PMID:
9144488

Supplemental Content

Support Center